Having trouble accessing articles? Reset your cache.

Tamibarotene: Phase IIb discontinued

CytRx discontinued a double-blind, international Phase IIb trial in 140 patients with stage IIIb/IV NSCLC after an interim analysis showed that first-line treatment with twice-daily oral tamibarotene

Read the full 278 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE